• | Previous ERCP |
• | Known allergy or intolerance to one of the compounds used in the study |
• | Participation in another interventional trial during the previous four weeks |
• | Pregnancy and breast feeding |
• | current acute pancreatitis |
• | Renal insufficiency ≥ stage 4 (K/DOQI), i.e. MDRD-GFR < 30 ml/min/1,73 m2) |
• | Hyperthyroidism |
• | Symptomatic bradycardia <35 bpm |
• | Atrioventricular block > 1° or other cardial conduction defects |
• | Myasthenia gravis |
• | Liver cirrhosis Child C |
• | Overt coagulopathy |
• | Kidney stone diathesis (calcium-magnesium-ammonium-phosphate stones) |
• | Mental impairment, addiction or other disorders leading to the patients inability to understand the scope and possible consequences of a participation in a clinical trial |
• | Magnesium medication within 14 days before the procedure |
• | Inability to give informed consent |